AN13: Health r&d services; health care services; experimental development
Research and Development · Figures are FPDS award actions reporting this code.
Research and development code
Active
Overview
- FY2026 obligations
- $1.11B
- $1,109,583,457awarded under AN13
- FY2027 to date
- -$3.07K
- -$3,06866 awards · year to date · net de-obligation
- FY2026 awards
- 309
- awards with an action under this code
Obligations by fiscal year of action
- FY2027: -$3,068 (de-obligation) (year to date)
- FY2026: $1,109,583,457
- FY2025: $116,604,929
- FY2024: $564,031,839
- FY2023: $1,397,678,204
- FY2022: $836,031,906
Total across 6 fiscal years: $4,023,927,266
Net de-obligation in that fiscal year (obligations withdrawn).
* Year to date.
Source: FPDS award actions reporting this PSC. Obligations are the sum of the obligation on each action (modifications included). Department of Defense actions appear about 90 days after they are signed.
Definition
- Official name
- HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT
- Category
- Research and Development
- Status
- Active since October 30, 2020
Top buying agencies
FY2024–FY2026 · awarding sub-tier agencies
| Rank | Agency | Obligated | |
|---|---|---|---|
| 1 | Office Of Assistant Secretary For Preparedness And Response | $1,383,807,912 | 77.3% |
| 2 | Departmental Offices | $223,854,069 | 12.5% |
| 3 | National Institutes Of Health | $179,464,453 | 10.0% |
| 4 | Defense Health Agency | $89,925,923 | 5.0% |
| 5 | Veterans Affairs, Department Of | $12,935,122 | 0.7% |
| 6 | Department Of The Army | $1,731,717 | 0.1% |
| 7 | Department Of The Navy | $599,925 | <0.1% |
| 8 | Food And Drug Administration | $498,057 | <0.1% |
Top vendors
FY2024–FY2026
| Rank | Vendor | Obligated | ||
|---|---|---|---|---|
| 1 | AMGEN USA INC. | $345,768,625 | 3 | 19.3% |
| 2 | SIGA TECHNOLOGIES, INC. | $167,743,809 | 1 | 9.4% |
| 3 | SHIONOGI INC | $156,103,541 | 1 | 8.7% |
| 4 | BATTELLE MEMORIAL INSTITUTE | $69,915,391 | 44 | 3.9% |
| 5 | HOFFMANN-LA ROCHE INC. | $67,872,020 | 1 | 3.8% |
| 6 | WESTAT, INC. | $65,635,451 | 4 | 3.7% |
| 7 | PUBLIC HEALTH VACCINES LLC | $60,426,909 | 1 | 3.4% |
| 8 | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | $58,441,680 | 3 | 3.3% |
| 9 | GENENTECH INC | $56,804,864 | 1 | 3.2% |
| 10 | LOCUS BIOSCIENCES INC | $48,826,300 | 1 | 2.7% |